

INFORMATION DISCLOSURE STATEMENT BY APPLICANT		Application No.	10/785,446
(Multiple sheets used when necessary)		Filing Date	February 23, 2004
SHEET 1 OF 2		First Named Inventor	Lauren Otsuki
		Art Unit	1614
		Examiner	ROYDS, Leslie A.
		Attorney Docket No.	NOCAR.007A

U.S. PATENT DOCUMENTS

Examiner Initials	Cite No.	Document Number Number - Kind Code (if known) Example: 1,234,567 B1	Publication Date MM-DD-YYYY	Name of Patentee or Applicant	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear
	1	4,769,377	09-06-1988	Sayder et al.	
	2	6,605,600	08-12-2003	Ensinger et al.	
	3	6,649,600	11-18-2003	Kiesman et al	
	4	7,022,686	04-04-2006	Lin	
	5	2004/0259889	12-23-2004	Smits et al.	
	6	2005/0038017	02-17-2005	Wolff et al.	
	7	2005/0070524	03-31-2005	Stephenson et al.	
	8	2005/0245546	11-03-2005	Cristalli	
	9	2006/0293312	12-28-2006	Dittrich et al.	
	10	2007/0238672	10-11-2007	Dittrich et al.	
	11	2007/0293463	12-20-2007	Dittrich et al.	
	12	2007/0293518	12-20-2007	Dittrich et al.	
	13	2008/0070934	03-20-2008	Mugerditchian et al.	
	14	Serial No. 12/058,532	?	Dittrich et al.	

FOREIGN PATENT DOCUMENTS

Examiner Initials	Cite No.	Foreign Patent Document Country Code-Number-Kind Code Example: JP 1234567 A1	Publication Date MM-DD-YYYY	Name of Patentee or Applicant	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear	T ¹
	15	EP 0 565 377	10-13-1993	Kyowa Hakko Kogyo KK		
	16	EP 0 958 821	11-24-1999	Kyowa Hakko Kogyo KK		
	17	JP 1979/79296	06-25-1979	Draco AB		Abstract Only
	18	JP 1984/42383	03-08-1984	Adir		Abstract Only

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /LAR/ (04/09/2009)

Examiner Signature	/Leslie A. Royds/ (04/09/2009)	Date Considered
--------------------	--------------------------------	-----------------

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

T¹ - Place a check mark in this area when an English language Translation is attached.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT		Application No.	10/785,446
(Multiple sheets used when necessary)		Filing Date	February 23, 2004
SHEET 2 OF 2		First Named Inventor	Lauren Otsuki
		Art Unit	1614
		Examiner	ROYDS, Leslie A.
		Attorney Docket No.	NOCAR.007A

NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ¹
	19	Anonymous "Protect-1: A study of the selective A1 Adenosine receptor antagonist KW-3902 for patients hospitalized with acute HF and volume overload to assess treatment effect on congestion and renal function." NovoCardia Study; www.clinicaltrials.gov/ct/show/NCT00328692?order=2 (05/19/2006)	
	20	Anonymous "Study to evaluate cardiac hemodynamics and safetyof SLV320 in subjects with congestive heart failure", Solvay Pharma. www.clinicaltrials.gov/ct/show/NCT00160134?ORDER=1 (09/08/2005)	
	21	AVSAR et al. "Adenosine acting via A1 receptors controls the transition to status epilepticus-like behaviour in an invitro model of epilepsy." <i>Neuropharmacology</i> . 47:427-437 (2004)	
	22	BARIANA, D.S. "7-(1-Isoquinolinylmethyl)-theophyllines", <i>Can J Chem.</i> (1968) 46(21): 3411-13	
	23	BEAUGLEHOLE et al., "Fluorosulfonyl-substituted xanthines as selective irreversible antagonists for the A(1)-adenosine receptor" <i>J Med Chem.</i> (2000) 43(26): 4973-80	
	24	KAPLAN et al. "Effects of benzodiazepine administration on A1 adenosine receptor binding in-vivo and ex-vivo." <i>J Pharm. Pharmacol.</i> (1992); 44(8):700-703.	
	25	MASSIE et al., "Evolving trends in the epidemiologic factors of heart failure: rationale for preventive strategies and comprehensive disease management", <i>Am Heart J.</i> , (1997) 133(6):703-12	
	26	McOMIE, J.F.W. "Protective Groups in Organic Chemistry", <i>Plenum Press</i> , London (1973)	
	27	PAPESCH et al.; "Synthesis of 1-Mono- and 1,3-Disubstituted 6-Aminouracils", <i>J Org Chem.</i> (1951); 16: 1879-1890	
	28	RICH et al.; "Cost-effectiveness analysis in clinical practice: the case of heart failure." <i>Arch Intern Med.</i> (1999) 159(15):1690-700	
	29	TREIMAN et al. "Treatment of seizure emergencies: Convulsive and non-convulsive status epilepticus." <i>Epilepsy Research.</i> (2006); 68S:S77-S82.	
	30	WIJKOON et al.; "The octant rule 21. Antioctant effects in δ -unsaturated ketones", <i>J. Org. Chem.</i> (1987); 52:4171-4175	
	31	EPO Communication in EP Patent Application No. 04714224.5; Dated 08/31/2006	
	32	EPO Communication in EP Patent Application No. 04714224.5; Dated 02/22/2008	
	33	International Search Report dated August 26, 2004 in PCT/US04/005755	
	34	International Preliminary Report on Patentability and Written Opinion dated August 26, 2005 in PCT/US04/005755	

5696029:abt
072308

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /LAR/ (04/09/2009)

Examiner Signature	/Leslie A. Royds/ (04/09/2009)	Date Considered
*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.		

T¹ - Place a check mark in this area when an English language Translation is attached.